Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis

[1]  Y. Lee,et al.  Placebo and nocebo responses in randomized controlled trials of Janus kinase inhibitor monotherapy for rheumatoid arthritis , 2021, Zeitschrift für Rheumatologie.

[2]  A. Barsky,et al.  Placebo and Nocebo Effects. , 2020, The New England journal of medicine.

[3]  D. Mitsikostas,et al.  Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis , 2020, Journal of Neurology.

[4]  D. Heijde,et al.  Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial , 2019, The Lancet.

[5]  Y. Lee,et al.  YKL-40 Levels in Rheumatoid Arthritis and Their Correlation with Disease Activity: A Meta-analysis , 2019, Journal of Rheumatic Diseases.

[6]  K. Kalunian,et al.  Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. , 2019, JAMA.

[7]  Siddharth Singh,et al.  Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2019, Journal of Crohn's & colitis.

[8]  R. Landewé,et al.  Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial , 2018, The Lancet.

[9]  G. Kitas,et al.  Nocebos in rheumatology: emerging concepts and their implications for clinical practice , 2018, Nature Reviews Rheumatology.

[10]  M. Genovese,et al.  Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial , 2018, The Lancet.

[11]  T. Jenkins,et al.  Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials , 2018, Journal of the Neurological Sciences.

[12]  P. Tak,et al.  Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study , 2017, The Lancet.

[13]  G. Burmester,et al.  Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors , 2016, Arthritis & rheumatology.

[14]  D. M. van der Heijde,et al.  Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study , 2016, Annals of the rheumatic diseases.

[15]  J. Kremer,et al.  Baricitinib in Patients with Refractory Rheumatoid Arthritis. , 2016, The New England journal of medicine.

[16]  Y. Lee,et al.  Meta-Analysis of Genetic Association Studies , 2015, Annals of laboratory medicine.

[17]  F. Benedetti,et al.  Placebo and Nocebo Effects , 2014 .

[18]  D. Mitsikostas,et al.  Nocebo in clinical trials for depression: A meta-analysis , 2014, Psychiatry Research.

[19]  Tamas Koncz,et al.  Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial , 2013, The Lancet.

[20]  P. Sfikakis,et al.  Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice , 2012, European journal of neurology.

[21]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[22]  P Tugwell,et al.  Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. , 2008, Arthritis and rheumatism.

[23]  G. Koch,et al.  Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations , 2008, Annals of the rheumatic diseases.

[24]  J. Kremer,et al.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial , 2008, Annals of the rheumatic diseases.

[25]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[26]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[27]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[28]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[29]  George Davey Smith,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[30]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[31]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[32]  R. Chang,et al.  The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[33]  Y. Lee,et al.  Associations Between Circulating Interleukin-17 Levels and Systemic Lupus Erythematosus and Between Interleukin-17 Gene Polymorphisms and Disease Susceptibility: A Meta-analysis , 2020 .

[34]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.